CEO Joseph Papa stated that "we had another great quarter and are on track to exceed our initial 2025 revenue and adjusted EBITDA guidance." He highlighted securing 11 contract modifications and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Emergent BioSolutions (EBS) downgraded to Hold as Narcan sales slip, competition rises and debt persists; review risks, cash flow signals and act now.

Emergent Biosolutions () has held its Q2 earnings call. Read on for the main highlights of the call. Summer Sale - Claim 70% Off TipRanks. Unlock powerful investing tools with Tip ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.

An analyst initiated coverage of Emergent BioSolutions (NYSE: EBS) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled into ...

CEO Joe Papa highlighted significant progress in Emergent's multiyear turnaround plan, focusing on stabilizing operations, streamlining costs, and driving sustainable growth. Key achievements in Q1 ...

Repurchase reduces unsecured note balance to approximately $364.7 million Management to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG, Md ...

As an mpox outbreak in Africa continues to spread, the FDA has approved an Emergent BioSolutions vaccine for preventing infection from this pathogen. The regulatory decision could be the first of ...

Emergent BioSolutions cut FY2026 revenue guidance to $645-$675 million after reaffirming a $720-$760 million outlook three months earlier. Levi & Korsinsky is investigating potential securities law ...